[1]杨 雪 杨吉安 综述 陈谦学 审校.Hippo信号通路与胶质瘤的研究进展[J].中国临床神经外科杂志,2017,(04):279-281.[doi:10.13798/j.issn.1009-153X.2017.04.029]
点击复制

Hippo信号通路与胶质瘤的研究进展()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2017年04期
页码:
279-281
栏目:
论著
出版日期:
2017-04-25

文章信息/Info

文章编号:
1009-153X(2017)04-0279-03
作者:
杨 雪 杨吉安 综述 陈谦学 审校
430060 武汉,武汉大学人民医院神经外科
关键词:
胶质瘤Hippo信号通路治疗
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2017.04.029
文献标志码:
A

参考文献/References:

[1] Preusser M, de Ribaupierre S, Wohrer A, et al. Current con- cepts and management of glioblastoma [J]. Ann Neurol, 2011, 70(1): 9-21.
[2] Genevet A, Tapon N. The Hippo pathway and apico-basal cell polarity [J]. Biochem J, 2011, 436(2): 213-224.
[3] Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology [J]. Trends Cell Biol, 2012, 22(7): 339- 346.
[4] Huo X, Zhang Q, Liu A M, et al. Overexpression of Yes- associated protein confers doxorubicin resistance in hepa- tocellullar carcinoma [J]. Oncol Rep, 2013, 29(2): 840-846.
[5] Zhou Z, Hao Y, Liu N, et al. TAZ is a novel oncogene in non-small cell lung cancer [J]. Oncogene, 2011, 30(18): 2181-2186.
[6] Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromo- some 11q22 amplicon [J]. Proc Natl Acad Sci USA, 2006, 103(33): 12405-12410.
[7] Kim NG, Koh E, Chen X, et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components [J]. Proc Natl Acad Sci USA, 2011, 108(29): 11930-11935.
[8] Schlegelmilch K, Mohseni M, Kirak O, et al. Yap1 acts downstream of alpha-catenin to control epidermal prolifera- tion [J]. Cell, 2011, 144(5): 782-795.
[9] Silvis MR, Kreger BT, Lien WH, et al. Alpha-catenin is a tumor suppressor that controls cell accumulation by regula- ting the localization and activity of the transcriptional coac- tivator Yap1 [J]. Sci Signal, 2011, 4(174): a33.
[10] Varelas X, Samavarchi-Tehrani P, Narimatsu M, et al. The Crumbs complex couples cell density sensing to Hippo- dependent control of the TGF-beta-SMAD pathway [J]. Dev Cell, 2010, 19(6): 831-844.
[11] Chan SW, Lim CJ, Chong YF, et al. Hippo pathway-inde- pendent restriction of TAZ and YAP by angiomotin [J]. J Biol Chem, 2011, 286(9): 7018-7026.
[12] Hirate Y, Hirahara S, Inoue K, et al. Polarity-dependent distribution of angiomotin localizes Hippo signaling in pre- implantation embryos [J]. Curr Biol, 2013, 23(13): 1181- 1194.
[13] Zhao B, Li L, Lu Q, et al. Angiomotin is a novel Hippo path- way component that inhibits YAP oncoprotein [J]. Genes Dev, 2011, 25(1): 51-63.
[14] Wang W, Huang J, Chen J. Angiomotin-like proteins asso- ciate with and negatively regulate YAP1 [J]. J Biol Chem, 2011, 286(6): 4364-4370.
[15] Paramasivam M, Sarkeshik A, Yates JR, et al. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor [J]. Mol Biol Cell, 2011, 22(19): 3725- 3733.
[16] Yi C, Troutman S, Fera D, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions [J]. Cancer Cell, 2011, 19(4): 527-540.
[17] Aragona M, Panciera T, Manfrin A, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors [J]. Cell, 2013, 154 (5): 1047-1059.
[18] Mo C, Wang L, Zhang J, et al. The crosstalk between Nrf2 and AMPK signal pathways is important for the anti- inflammatory effect of berberine in LPS-stimulated macro- phages and endotoxin-shocked mice [J]. Antioxid Redox Signal, 2014, 20(4): 574-588.
[19] Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treat- ment [J]. Nat Rev Drug Discov, 2013, 13(1): 63-79.
[20] Tang F, Zhang L, Xue G, et al. hMOB3 modulates MST1 apoptotic signaling and supports tumor growth in glioblast- oma multiforme [J]. Cancer Res, 2014, 74(14): 3779-3789.
[21] Chao Y, Wang Y, Liu X, et al. Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway [J]. J Neuro-Oncol, 2015, 121(2): 279-288.
[22] Zhu G, Wang Y, Mijiti M, et al. Upregulation of miR-130b enhances stem cell-like phenotype in glioblastoma by in- activating the Hippo signaling pathway [J]. Biochem Bioph Res Co, 2015, 465(2): 194-199.
[23] Jiang Z, Li X, Hu J, et al. Promoter hypermethylation- mediated down-regulation of LATS1 and LATS2 in human astrocytoma [J]. Neurosci Res, 2006, 56(4): 450-458.
[24] Ji T, Liu D, Shao W, et al. Decreased expression of LATS1 is correlated with the progression and prognosis of glioma [J]. J Exp Clin Cancer Res, 2012, 31(1): 67.
[25] Lignitto L, Arcella A, Sepe M, et al. Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth [J]. Nat Commun, 2013, 4: 1822.
[26] Liu Y, Wang Y. Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects [J]. Tumor Biol, 2015, 36(4): 2223-2227.
[27] Orr B A, Bai H, Odia Y, et al. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth [J]. J Neuropathol Exp Neurol, 2011, 70(7): 568-577.
[28] Artinian N, Cloninger C, Holmes B, et al. Phosphorylation of the Hippo pathway component AMOTL2 by the mTORC2 kinase promotes YAP signaling, resulting in enhanced glioblastoma growth and invasiveness [J]. J Biol Chem, 2015, 290(32): 19387-19401.
[29] Liu Y, Wang Y. Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects [J]. Tumor Biol, 2015, 36 (4): 2223-2227.
[30] Bhat KP, Salazar KL, Balasubramaniyan V, et al. The trans- criptional coactivator TAZ regulates mesenchymal differen- tiation in malignant glioma [J]. Genes Dev, 2011, 25(24): 2594-2609.
[31] Tian T, Li A, Lu H, et al. TAZ promotes temozolomide resis- tance by upregulating MCL-1 in human glioma cells [J]. Biochem Bioph Res Co, 2015, 463(4): 638-643.
[32] Yuan J, Xiao G, Peng G, et al. MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differenti- ation by targeting TAZ [J]. Biochem Bioph Res Co, 2015, 457(2): 171-176.
[33] Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treat- ment [J]. Nat Rev Drug Discov, 2014, 13(1): 63-79.

相似文献/References:

[1]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
 CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(04):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
 XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(04):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
 LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(04):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波 杨宇焦 张 逵 范润金 张 渊 杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
 YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(04):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚 成于思 王 辉 汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
 HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(04):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林 雨 张 恺 李 帅 杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明 徐成仕 王泽芬 曹长军 李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
 DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生 田道锋 张申起 陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
 PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯 驰 郭双毅 程龙海 罗 杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
 FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]

更新日期/Last Update: 2017-04-25